Rochester, MNNCT07148089Now EnrollingIRB Ready

Catecholaminergic Polymorphic Ventricular Tachycardia Clinical Trial in Rochester, MN

Access cutting-edge catecholaminergic polymorphic ventricular tachycardia treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.

Sponsored by Solid Biosciences Inc.

Quick Self-Assessment

See if you qualify for this Rochester location

Preparing your pre-screening questions…

Expert Care in Rochester

Access catecholaminergic polymorphic ventricular tachycardia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related catecholaminergic polymorphic ventricular tachycardia treatment provided free

Apply for This Rochester Location

Check if you qualify for this catecholaminergic polymorphic ventricular tachycardia clinical trial in Rochester, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Rochester

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Rochester site if eligible
  4. 4Begin participation

About This Catecholaminergic Polymorphic Ventricular Tachycardia Study in Rochester

This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus on obtaining safety data in adult participants. Cohort 1 and Cohort 2 (optional for dose exploration) will include participants ≥ 18 years of age. Cohort 3 will include participants ≥ 7 to \< 18 years of age and will be initiated following data and safety monitoring board (DSMB) recommendations. Participants will be monitored for 5 years post-administration of SGT-501 including the active treatment period (1 year) and long-term follow-up (LTFU) (4 years) period.

Sponsor: Solid Biosciences Inc.

Who Can Participate

Inclusion Criteria

Type of Participant and Disease Characteristics:
Clinical diagnosis of CPVT, based on documented history of polymorphic or bidirectional non-sustained ventricular tachycardia with exercise or ventricular ectopy in a pattern consistent with CPVT on EST.
Central Screening laboratory determination of a RYR2 variant that is pathogenic or likely pathogenic for CPVT.
Documented history of life-threatening ventricular arrhythmic event defined as: survived sudden cardiac arrest, sudden cardiac arrest with appropriate implantable cardioverter defibrillator (ICD) shock, arrhythmic syncope, or sustained ventricular tachycardia (30 seconds or more) with or without ICD shock.
On stable dose (defined as no change in dose by more than 50% for at least 1 month prior to Screening) of standard-of-care therapy defined as a beta-blocker and/or flecainide.
Documented prior history of EST demonstrating a ventricular arrythmia score (VAS) score of ≥ 2.
For the first 2 participants in each cohort only: a properly functioning ICD device in place. Following review of data from Cohorts 1 and 2, the Data Safety and Monitoring Board (DSMB) will determine if this criterion is required for participants in Cohort 3.
Must be up to date with meningococcal vaccination per national guidelines or willing to receive meningococcal vaccine to achieve this.
Other inclusion criteria to be applied as per protocol.

Exclusion Criteria

Abnormal liver function: gamma-glutamyl transferase (GGT) \> 1.5 × upper limit of normal \[ULN\] or total bilirubin \> ULN).
Abnormal renal function defined by estimated glomerular filtration rate \< 60 milliliter /minute (mL/min)/1.73-square meter (m\^2) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula.
Clinically significant abnormalities of coagulation including international normalized ratio or activated partial thromboplastin time \> 1.2 × ULN or platelets \< 150,000 cells/cubic millimeter (mm\^3).
Potential concomitant cardiomyopathy or inherited arrhythmia as evidenced by pathogenic or likely pathogenic mutation other than RYR2 obtained on cardiac panel during Screening.
Current or prior treatment with an approved or investigational gene transfer drug.
Exposure to another investigational drug within 90 days prior to Screening or 5 half-lives since last administration, whichever is longer.
Contraindication or unwillingness to receive required immunosuppression regimen.
Body mass index ≥ 30 kilograms per square meter (kg/m\^2).
Other exclusion criteria to be applied as per protocol.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT07148089) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Catecholaminergic Polymorphic Ventricular Tachycardia Treatment Options in Rochester, MN

If you're searching for catecholaminergic polymorphic ventricular tachycardia treatment options in Rochester, MN, this clinical trial (NCT07148089) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced catecholaminergic polymorphic ventricular tachycardia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all catecholaminergic polymorphic ventricular tachycardia clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Rochester, MN

See all heart attack clinical trials recruiting in Rochester — not just this study.

Browse Heart Attack Trials in Rochester →

Browse More Trials by Condition

Heart Attack TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsRetinitis Pigmentosa TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Rochester?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Rochester, MN